TETRALOGIC PHARMACEUTICALS CORP LAS VEGAS, NY / ACCESSWIRE / June 27, 2016 / A few biotech companies could be set to heat up now that the summer is officially here.
Endonovo Therapeutics, Inc. (ENDV) is currently at the forefront of a revolutionary approach to treating injuries and illnesses called bioelectronic medicine. This rapidly emerging segment of medicine seeks to harness the electrical impulses cells and nerves use to control inflammation and healing in tissues and organs. What really sets Endonovo apart from its competitors is ENDV non-invasive device does not require implantation into patients. ENDV's technology uses rapidly changing magnetic fields to deliver electrical stimulation deep into tissues, an effect known as Faraday coupling, which is the same fundamental operating principle of transformers and many types of electrical motors and solenoids. Endonovo uses these platform technologies to both directly reduce inflammation via a non-invasive medical device and grow and enhance stem cells for cell therapies and tissue engineering.
Recently, the company received a price target of $1.15 from See Thru Equity research. With the company currently priced at 25 cents a share, reaching the target price would represent a 360% price gain.
The report cites ENDV's "potentially disruptive Immunotronics? and Cytotronics? platforms."
as a major driver behind their valuation. The report also cited a few major upcoming events that could drive their target even higher:
- 2H2016E Immunotronics Preclinical study for liver disease
- 1H2017E Immunotronics IDE application submitted to FDA
- 1H2017E Cytotronics Orphan Drug Designation for Graft versus Host Disease
- 1H2017E Estimated $2mn $5mn financing; possibly in conjunction with a listing on a national exchange
- 2H2017E Immunotronics Human clinical trials begin
About Immunotronics
ENDV's Immunotronics platform is being developed to control inflammation in vital organs in order to treat and prevent organ failure and other inflammatory conditions, such acute liver injury. ENDV's initial concentration focuses on treating inflammation in the liver and augmenting its regeneration using its non-invasive medical device.
BCC Research's most recent report on the global market for liver disease therapeutics, found approximately $24.5 billion was spent in 2014 treating liver diseases and expects the investment in liver disease to grow to $33.8 billion by 2019, a CAGR of 6.7 percent.
About Cytotronics
ENDV's other large opportunity lies in their Cytotronics platform, which uses electrical stimulation to produce more potent stem cells. ENDV is initially focused on treating Graft Versus Host Disease "GVHD" and expanding the use and effectiveness of cord blood stem cells. GVHD, occurs when cells from a transplanted organ attack the recipient's body. GVHD primarily occurs following a stem cell, bone marrow or tissue transplant.
Global spending treating the disease was about $300 million in 2013 and is expected to grow at a CAGR of 12.8 percent to $545 million in 2023 according to research from Future Markets Insight. This is another major opportunity for Endonovo.
Tetralogic Pharmaceuticals Corp. (TLOG) had a huge day Monday, up 62% on over 5 million shares; this stock is receiving serious interest and you should start paying attention too.
Lpath, Inc. (LPTN) shares are skyrocketing, up over 58% in afternoon trading after the company announced that it has been awarded a $1.45 million twoyear grant by the Defense Medical Research and Development Program (DMRDP), which is an agency of the U.S. Department of Defense (DOD).
Fate Therapeutics, Inc. (FATE) another next generation stem cell company like ENDV, has surged by over 20% after the company said the U.S. Food and Drug Administration (FDA) has granted Fast Track status to ProTmune, its drug for the reduction of the incidence and severity of acute graftversushost disease (GvHD). The San Diego, California based biopharmaceutical company also announced that Phase 1/2 clinical trial of ProTmune in adult subjects with hematologic malignancies is open for patient enrollment. In a statement, Chris Storgard, M.D., Chief Medical Officer of Fate Therapeutics, said that the company is looking forward to work with FDA to "rapidly advance" its innovative immunotherapy through the clinical development and regulatory processes.
Minerva Neurosciences (NERV) surged ahead of their presentation Tuesday at the JMP Securities Life Sciences Conference in New York.
A biopharmaceutical player that's starting to trend within range of triggering a big breakout trade is NewLink Genetics (NLNK), which focuses on discovering, developing and commercializing immunotherapeutic products to enhance treatment options for patients with cancer. This stock had been destroyed by the bears over the last six months, with shares down big by 70.7%.
If you take a glance at the chart for NewLink Genetics, you'll notice that this stock recently formed a double bottom chart pattern, after shares found some buying interest at $9.76 to $9.84 a share. Following that potential bottom, this stock has now started to spike higher off those support levels, and it's quickly trending within range of triggering a nearterm breakout trade above some key overhead resistance levels.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. For Full Legal Disclaimer Click Here.
SOURCE: ACR Communication, LLC
